secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2023-10-06T23:59:59+00:00
Accession:  0000950170-23-052242
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen appoints Thane Wettig as permanent CEO and Board member, effective Oct 2, 2023
--------------------------------------------------------------------------------

- Thane Wettig promoted from Interim CEO to CEO and Board member as of Oct 2, 2023.
- Mr. Wettig had served as Interim CEO since July 23, 2023.
- Appointed as Class I director with term expiring at 2024 annual meeting.
- Compensation terms remain per prior 8-K filed July 25, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017023052242/0000950170-23-052242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017023052242/fgen-20231002.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-052242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer